The AKAP9 Knockout HEK293T Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population targeting the AKAP9 gene (A-kinase anchoring protein 9) in the human embryonic kidney-derived HEK293T host cell line. This product provides a heterogeneous pool of loss-of-function models for studying the scaffolding protein AKAP9, which organizes signaling complexes at the centrosome and Golgi apparatus. By disrupting the AKAP9 locus via CRISPR/Cas9-mediated gene disruption, this polyclonal population enables functional interrogation of AKAP9-dependent processes without prior clonal isolation. The knockout model is suitable for pooled assays and high-throughput screening approaches where polyclonal representation enhances biological robustness.
The host cell line, HEK293T, is a well-established derivative of HEK293 cells that stably expresses the SV40 large T-antigen. This modification supports high-level protein expression and episomal replication of plasmids containing the SV40 origin of replication, making HEK293T a preferred system for transient protein production, lentiviral packaging, and biochemical signaling studies. The epithelial phenotype and human origin of HEK293T cells provide a physiologically relevant context for investigating centrosome biology, cAMP/PKA signaling, and cell cycle regulation. The robust growth characteristics and ease of transfection further facilitate downstream applications such as immunofluorescence, co-immunoprecipitation, and functional rescue experiments.
AKAP9 encodes a large scaffold protein that anchors protein kinase A (PKA) via its regulatory subunits (notably RII??), along with other signaling enzymes such as phosphodiesterase PDE4D3 and phosphatases PP2A and PP1, to the centrosome and Golgi. Through these interactions, AKAP9 spatially compartmentalizes cAMP signaling downstream of G protein-coupled receptors and adenylyl cyclase activation. AKAP9 is regulated by upstream kinases including Aurora A and PLK1, and it organizes microtubule dynamics and mitotic spindle formation by recruiting ??-tubulin, pericentrin, CEP68, and CEP170. Disruption of AKAP9 therefore impairs PKA substrate phosphorylation, centrosome maturation, and cell cycle progression, and it has been linked to defects in ciliogenesis. This scaffold is implicated in diseases such as Long QT syndrome, cardiac arrhythmias, and cancer.
In the HEK293T background, AKAP9 knockout provides a powerful tool to dissect compartmentalized cAMP/PKA signaling and centrosome-dependent processes. Because HEK293T cells are amenable to high-efficiency transfection and robust protein expression, this knockout model is well-suited for biochemical reconstitution experiments, where wild-type or mutant AKAP9 constructs can be reintroduced to map functional domains and interaction partners. The polyclonal nature of the product permits pooled analyses that average over clonal variations, which is advantageous for unbiased proteomic or transcriptomic profiling. Moreover, the ease of culturing HEK293T cells supports scalable assays for mitotic index determination, ciliogenesis induction, and drug response studies.
Researchers can utilize this AKAP9 knockout polyclonal cell population for a wide range of applications, including centrosome biology studies, investigation of cAMP/PKA signal compartmentalization, mitotic progression analyses, and ciliogenesis research. Representative assays include Western blotting to assess PKA subunit expression and substrate phosphorylation, immunofluorescence microscopy using markers such as ??-tubulin and GM130, co-immunoprecipitation to probe protein interactions, flow cytometry for cell cycle distribution, and high-content screening for modulators of AKAP9-dependent processes. This model also supports RNA-seq and phospho-proteomic discovery workflows to identify downstream targets and signaling networks. For further experimental customization or technical inquiries, please contact Ascent Research.
